These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

615 related items for PubMed ID: 28276777

  • 1. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R, Alikhan A.
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L, Del Duca E, Romanelli M, Saraceno R, Chimenti S, Chiricozzi A.
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
    [Abstract] [Full Text] [Related]

  • 3. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O.
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [Abstract] [Full Text] [Related]

  • 4. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
    Torres T, Puig L.
    Am J Clin Dermatol; 2018 Feb; 19(1):23-32. PubMed ID: 28597182
    [Abstract] [Full Text] [Related]

  • 5. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S, Kavanaugh A.
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [Abstract] [Full Text] [Related]

  • 6. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A, Del Duca E, Saraceno R, Gramiccia T, Bianchi L.
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V.
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [Abstract] [Full Text] [Related]

  • 8. An update on the safety of apremilast for the treatment of plaque psoriasis.
    Shavit E, Shear NH.
    Expert Opin Drug Saf; 2020 Apr; 19(4):403-408. PubMed ID: 32182143
    [Abstract] [Full Text] [Related]

  • 9. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M, Komine M, Hioki T, Kamiya K, Sugai J, Ohtsuki M.
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [Abstract] [Full Text] [Related]

  • 10. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG.
    J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
    [Abstract] [Full Text] [Related]

  • 11. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
    Chiricozzi A, Caposiena D, Garofalo V, Cannizzaro MV, Chimenti S, Saraceno R.
    Expert Rev Clin Immunol; 2016 Aug; 12(3):237-49. PubMed ID: 26692125
    [Abstract] [Full Text] [Related]

  • 12. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC, McNamee KE, McCann FE.
    Drug Des Devel Ther; 2013 Aug; 7():201-10. PubMed ID: 23569359
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
    Paller AS, Hong Y, Becker EM, de Lucas R, Paris M, Zhang W, Zhang Z, Barcellona C, Maes P, Fiorillo L.
    J Am Acad Dermatol; 2020 Feb; 82(2):389-397. PubMed ID: 31408686
    [Abstract] [Full Text] [Related]

  • 14. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J.
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [Abstract] [Full Text] [Related]

  • 15. Apremilast for the treatment of psoriasis.
    Chimenti MS, Gramiccia T, Saraceno R, Bianchi L, Garofalo V, Buonomo O, Perricone R, Chimenti S, Chiricozzi A.
    Expert Opin Pharmacother; 2015 Mar; 16(13):2083-94. PubMed ID: 26243735
    [Abstract] [Full Text] [Related]

  • 16. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, Sebastian M.
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [Abstract] [Full Text] [Related]

  • 17. Apremilast as a treatment for psoriasis.
    Shutty B, West C, Pellerin M, Feldman S.
    Expert Opin Pharmacother; 2012 Aug; 13(12):1761-70. PubMed ID: 22712800
    [Abstract] [Full Text] [Related]

  • 18. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
    Sobell JM, Foley P, Toth D, Mrowietz U, Girolomoni G, Goncalves J, Day RM, Chen R, Yosipovitch G.
    Acta Derm Venereol; 2016 May; 96(4):514-20. PubMed ID: 26837052
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
    Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG.
    J Drugs Dermatol; 2018 Aug 01; 17(8):835-840. PubMed ID: 30124722
    [Abstract] [Full Text] [Related]

  • 20. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M, Papp K.
    BioDrugs; 2015 Oct 01; 29(5):327-39. PubMed ID: 26481941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.